Understanding the pathways that control epithelial carcinogenesis is vital to the development of effective treatments. The Polycomb group family member Bmi1 is overexpressed in numerous epithelial tumors, but its role in their development has not been established. We now show a key role for Bmi1 in lung adenocarcinoma. Whereas lung development occurs normally in Bmi1-deficient mice, loss of Bmi1 decreases the number and progression of lung tumors at a very early point in an oncogenic K-ras-initiated mouse model of lung cancer. This correlates with a defect in the ability of Bmi1-deficient putative bronchiolalveolar stem cells (BASCs) to proliferate in response to the oncogenic stimulus. Notably, in the absence of oncogenic K-ras, Bmi1-deficient BASCs show impaired proliferation and self-renewal capacity in culture and after lung injury in vivo. Abrogated lung cancer development and BASC self-renewal occur partially in a p19 ARF -dependent manner. Our data suggest that Bmi1 deficiency suppresses tumor development by limiting the expansion potential of BASCs, the apparent lung cancer cells of origin. Because Bmi1 is elevated in additional tumor types, this suggests that Bmi1 plays a key role in regulating proliferation of both stem cells and tumor cells in diverse adult epithelial tissues.
C
ancers of epithelial origin are the most prevalent tumors in adults (1) , yet little is known about the requirements for initiation and maintenance of these solid tumors. Lung cancer is the most common epithelial tumor and the leading cause of cancer death worldwide. Analysis of human tumors has identified a number of dysregulated genes that are associated with lung cancer including the Polycomb group member, Bmi1, which is overexpressed in non-small-cell lung cancer (NSCLC) and other epithelial malignancies, including colorectal carcinoma and liver carcinoma (reviewed in ref. 2) . In particular, Bmi1 overexpression is correlated with poor prognosis for lung cancer patients (3) . Bmi1 is an epigenetic chromatin modifier that acts as a key component of the PRC1 complex to mediate transcriptional repression. It was initially identified as an oncogene that cooperates with c-myc in generation of B-cell lymphomas (4, 5). The oncogenic potential of Bmi1 is, in part, because of negative regulation of the Ink4a/Arf locus that encodes two proteins, p16 INK4a and p19 ARF , that suppress proliferation and promote apoptosis (6, 7) .
Notably, Bmi1 has been implicated in the control of tissue stem cells and the tumors to which they may give rise. Analysis of Bmi1-deficient animals reveals the presence of defects in hematopoiesis and both the central and peripheral nervous systems (8) . Characterization of these defects demonstrates that Bmi1 is required for self-renewal of hematopoietic and neural stem cells (9, 10) . In addition to its effect on these normal cell compartments, Bmi1 deficiency suppresses hematopoietic malignancy (11) , and leukemic stem cells lacking Bmi1 fail to propagate disease (12) . Similarly, granule cell precursors from Bmi1-null animals show decreased proliferation, and medulloblastomas arising from this cell type have increased levels of Bmi1 (13) . Loss of Ink4a/Arf partially rescues Bmi1-null hematopoietic and neurosphere self-renewal capacity and restores transformation potential to Bmi1-deficient hematopoietic progenitors (11, 14, 15) . Similarly, Bmi1 contributes to glioma development through a combination of Ink4a/Arf-dependent and -independent mechanisms (16) . Apart from the skeletal, hematopoietic, and neural defects, all other tissues in Bmi1 null animals, including the lungs, appear normal.
Several populations of putative stem or progenitor cells have been identified in the adult murine lung, providing a means to address the possible connections between maintenance of adult lung tissue and lung tumorigenesis (17, 18) . Particularly in the distal lung where lung adenocarcinomas most frequently arise, the nonciliated bronchiolar cells, Clara cells, and the secretory epithelial cells in the alveolar space, alveolar type II (AT2) cells, have been implicated as stem or progenitor cells. Lung injury studies suggest that a population of damage-resistant, or ''variant'', Clara cells are stem or progenitor cells that repair damaged Clara cells (19, 20) . Expanding on these seminal studies, we identified a putative pulmonary stem cell population called bronchioalveolar stem cells (BASCs). BASCs coexpress SP-C, a marker of AT2 cells, and Scgb1a1, a marker of Clara cells (also known as CCSP, CCA, and CC10) (21, 22) , and reside in the bronchioalveolar duct junction (BADJ). BASCs proliferate before Clara cells, in response to Clara cell injury, and also respond to alveolar cell injury in vivo. BASCs exhibit bona fide stem cell characteristics in vitro. BASCs have self-renewal capacity, and they can give rise to both bronchiolar and alveolar cells in culture. Thus, we hypothesize that BASCs are a distal lung stem cell that maintains bronchiolar and alveolar homeostasis. Importantly, BASCs are the initial cells to proliferate in response to activation of oncogenic Ras in vivo (22) . Thus, BASCs appear to be the cell of origin for lung adenocarcinomas initiated by oncogenic K-ras.
We were intrigued by the observations that Bmi1 is overexpressed in NSCLC, and that Bmi1 has been implicated in stem cell maintenance and tumorigenicity in other tumors. Thus, we examined the consequences of Bmi1 deficiency in a murine lung cancer model and in BASCs to determine whether Bmi1 impacts the tumorigenic capacity of tissues that develop normally in the absence of Bmi1. Our analysis shows that K-ras-induced lung tumorigenesis is impaired in Bmi1-null animals. Additionally, Bmi1 is necessary for BASC proliferation and self-renewal in vivo and in culture. Our data suggest that Bmi1 serves an unrecognized role in epithelial tumorigenesis and provide a molecular link between putative lung stem cells and lung tumorigenesis.
Results

Loss of Bmi1 Abrogates Lung Tumorigenesis in Oncogenic K-ras Mice.
Given the observed overexpression of Bmi1 in human lung cancers and the requirement for Bmi1 in lymphomagenesis, we hypothesized that Bmi1 would also play a role in lung tumorigenesis. To investigate this possibility, we crossed mice carrying an inactivated Bmi1 gene (8) and a latent oncogenic K-ras G12D allele (K-ras LA2 ) that is activated by spontaneous in vivo recombination (23) . K-ras LA2 mice developed lung tumors with complete penetrance and lesions are first detectable at 1 week of age. Importantly, the age of onset of this tumor phenotype occurred well within the 3 month lifespan of the Bmi1-null animals.
At both 4 and 9 weeks of age, K-ras LA2 ;Bmi1 ϩ/ϩ , K-ras LA2 ;Bmi1 ϩ/Ϫ , and K-ras LA2 ;Bmi1 Ϫ/Ϫ mice were killed and examined for visible lung tumors (Fig. 1A ). There were no detectable differences in lung morphology or the ratio of lung size to body weight between Bmi1 Ϫ/Ϫ and WT mice, demonstrating that loss of Bmi1 has no noticeable effect on lung development (data not shown). However, there was a significant reduction in the number of visible tumors at both 4 and 9 weeks in K-ras LA2 ;Bmi1 Ϫ/Ϫ animals compared with either K-ras LA2 ;Bmi1 ϩ/ϩ or K-ras LA2 ;Bmi1 ϩ/Ϫ animals ( Fig. 1B ; P Ͻ 0.00001 and P ϭ 0.003, 4 and 9 weeks, respectively). In addition, at 9 weeks, the difference in lesions in K-ras LA2 ;Bmi1 ϩ/ϩ and K-ras LA2 ;Bmi1 ϩ/Ϫ mice was also highly significant (P ϭ 0.0004). Screening for the earliest detectable lesions by histopathological examination also detected a marked decrease in the number of early lesions in the K-ras LA2 ;Bmi1 Ϫ/Ϫ animals compared with K-ras LA2 ;Bmi1 ϩ/Ϫ or K-ras LA2 ;Bmi1 ϩ/ϩ animals [supporting information (SI) Fig. S1 ]. Taken together, these data demonstrate a dose-dependent requirement for Bmi1 in early lung tumor development.
In addition to determining that loss of Bmi1 affects the number of lung tumors, we also examined the effect of Bmi1 deficiency on tumor progression. We observed the early stage lesions of atypical adenomatous hyperplasia (AAH) and grade 1 alveolar adenoma at approximately equal levels in both the K-ras LA2 ;Bmi1 ϩ/ϩ and K-ras LA2 ;Bmi1 ϩ/Ϫ animals (Fig. 1C) . In contrast, there was a dramatic shift in tumor spectrum in the K-ras LA2 ;Bmi1 Ϫ/Ϫ animals: the infrequently observed lesions were entirely AAH (Fig. 1C) . These data suggest that loss of Bmi1 also impairs tumor progression. Taken together, these observations indicate that Bmi1 deficiency does not prevent transformation, per se, but rather blocks tumor development at a very early point during the earliest hyperplastic stage.
Bmi1-Null Lung Lesions Have Decreased Proliferation and Are Partially
Rescued by Loss of p19 ARF . We wished to establish how Bmi1 deficiency blocks progression of lung lesions in this model. Because we found no significant apoptosis in WT or Bmi1-null lung lesions (Fig. S2) , we examined the amount of cellular proliferation given Bmi1's role in its regulation (6) . Immunohistochemical analysis of Ki67 expression indicated that there was a reduction in the percentage of cycling cells in K-ras LA2 ;Bmi1 and Fig. S2 ). The Ki67-positive status of A AH in K-ras LA2 ;Bmi1 Ϫ/Ϫ mice was 2.5-fold lower than AAH or grade 1 adenomas in K-ras LA2 ;Bmi1 ϩ/ϩ mice (P Ͻ 0.0001). These data suggest that the decreased number and grade of lung lesions in Bmi1 Ϫ/Ϫ versus Bmi1 ϩ/ϩ animals correlate with a loss of proliferative capacity rather than a change in apoptosis.
A potential cause for the decreased cycling status of the lung tumors is the misregulation of the Ink4a/Arf locus. Bmi1 has been shown to be an important regulator of Ink4a/Arf, and expression of both p16 and p19 ARF is increased in cells deficient for Bmi1 (6) . Because derepression of these two genes can impair cell cycle progression and impact tumorigenesis, we examined the level of p16 and p19 ARF mRNA in total lung from both Bmi1 ϩ/ϩ and Bmi1 Ϫ/Ϫ animals at Ϸ7 weeks of age. Levels of p19 ARF were 19 Ϯ 5-fold greater in Bmi1 Ϫ/Ϫ lungs compared with WT lungs (P Ͻ 0.001). Levels of p16 were not significantly greater (P ϭ 0.2) nor were levels of p15 transcript from the neighboring INK4b locus ( Fig. 2B ; data not shown). This indicates that Bmi1 is required for appropriate repression of Arf in the lung.
To determine the extent to which misregulation of p19 ARF is responsible for the Bmi1-null tumor phenotypes, we interbred the K-ras LA2 ;Bmi1 compound mutant animals with Arf mutant animals (24) and quantified tumor number at 9 weeks of age. Whereas loss of Arf increased the number of tumors in K-ras LA2 ;Bmi1 Ϫ/Ϫ ;Arf Ϫ/Ϫ animals to the same level as in K-ras LA2 ;Bmi1 ϩ/ϩ animals, the K-ras LA2 ;Bmi1 ϩ/ϩ ;Arf Ϫ/Ϫ animals exhibited an even greater number of tumors (Fig. 2C) . A similar effect was also seen on tumor stage: loss of either one or both copies of Arf increased the percentage of advanced stage tumors in both K-ras LA2 ;Bmi1 ϩ/ϩ and K-ras LA2 ;Bmi1 Ϫ/Ϫ animals (Figs. 2D and S3). Although the loss of Arf in Bmi1-null lung increased the stage of lung lesions, such that we detected adenomas (40%) and occasional adenocarcinomas (6%), this did not approach the much higher frequency of adenomas (60%) and adenocarcinomas (28%) seen in the Bmi1,WT; Arf-null animals. This suggests that, though Arf plays a role in the suppression of tumors caused by loss of Bmi1, there are additional downstream targets that are also necessary for tumor formation.
Bmi1-Deficient BASCs Fail to Expand In Vivo.
The presence of BASCs in mouse lung adenocarcinomas and the documented expansion of BASCs in response to oncogenic K-ras supports the hypothesis that BASCs are the tumor-initiating cells in K-ras G12D -induced lung tumors (21, 22) . Given that Bmi1 affects very early tumorigenesis, we were interested in exploring the role of Bmi1 in BASCs. We identified BASCs in tissue sections at the BADJ by using dual immunofluorescence (IF) for SP-C and Scgb1a1 (Fig.  3A) . Analysis of terminal bronchioles (TBs) from single sections determined that there was no difference in the number of BASCs in WT and Bmi1 Ϫ/Ϫ mice at 9 weeks of age ( Fig. 3B ; P ϭ 0.75).
Having established that Bmi1 loss is not affecting early tumorigenesis by simply reducing the starting numbers of BASCs, we next asked whether the Bmi-null BASCs were capable of expanding in response to oncogenic K-ras. Our analysis showed a significant increase in the number of BASCs per TB when the K-ras LA2 allele was expressed in the Bmi1 ϩ/ϩ animals ( Fig. 3 B and C ; P Ͻ 0.0001). In contrast, BASCs in K-ras LA2 ;Bmi1 Ϫ/Ϫ mice exhibited a significantly reduced expansion (P Ͻ 0.0001). As with the tumor analyses, the loss of p19 ARF in the Bmi1-null animals allowed BASC numbers to expand to levels indistinguishable from K-ras LA2 WTs (P ϭ 0.5), and the loss of p19 ARF in the presence of Bmi1 further increased BASC expansion in response to oncogenic K-ras ( Fig. 3C ; P ϭ 0.02). These data indicate that Bmi1 is required for the K-ras-induced expansion of BASCs in vivo in a partially p19 ARF -dependent manner, linking a defect in BASCs to reduced lung tumorigenesis in Bmi1-deficient mice.
We wished to determine whether the impaired expansion of BASCs observed in the K-ras LA2 ;Bmi1 Ϫ/Ϫ lungs reflects a specific defect in the response to oncogenic K-ras or a more general failure to respond to proliferative signals. In the absence of lung injury, the distal pulmonary epithelial cells are rarely proliferative. Thus, we do not detect BASC proliferation unless the cells are subjected to oncogenic stimuli or lung injury, or they are removed from the niche and placed into culture (22) . Thus, we administered naphthalene to Ϸ8-week-old WT and mutant mice to ablate Clara cells and stimulate BASC expansion (20, 22, 25) . In contrast to WT mice, naphthalene-treated Bmi1 Ϫ/Ϫ mice did not demonstrate a significant expansion of BASCs at 1 week after naphthalene treatment ( Fig. 3D ; P ϭ 0.7 compared with Bmi1 Ϫ/Ϫ corn oil controls; P Ͻ 0.001 compared with naphthalene-treated Bmi1 ϩ/ϩ animals). Additionally, the extent of repair of Clara cells was impaired in Bmi1-null animals at both 1 week and 1 month after injury (Fig. 3 E and F ; P Յ 0.01). This repair defect was accompanied by a failure of Bmi1 Ϫ/Ϫ BASCs to proliferate at early time points after injury, as measured by BrdU incorporation (data not shown). These data indicate that Bmi1 is required for BASC expansion and the ability to replenish Clara cells after lung injury in vivo.
Bmi1-Deficient BASCs Demonstrate Defective Proliferation and Self-
Renewal in Culture. We next studied the performance of Bmi1-deficient BASCs, in culture conditions that support self-renewal or differentiation, to further explore the role of Bmi1 in BASCs. We isolated BASCs from Ϸ7-week-old WT, Bmi1 ϩ/Ϫ , and Bmi1 Ϫ/Ϫ animals ( Fig. S4 ; data not shown) and plated the cells on feeders for limiting dilution analysis. Consistent with our results showing the lack of expansion of Bmi1-null BASCs in vivo in response to oncogenic signaling or injury (Fig. 3) , Bmi1-deficient BASCs in culture exhibited a defect in proliferation. Primary epithelial colonies formed from all genotypes (Fig.  S5A ), yet colonies from Bmi1 Ϫ/Ϫ cells were significantly smaller than colonies from either WT or Bmi1 ϩ/Ϫ populations ( Fig. 4A ; P ϭ 0.0003 and P ϭ 0.01, respectively). This indicates that Bmi1 influences BASC proliferation in culture in a dose-dependent manner. Additionally, the limiting dilution analysis of the primary colonies demonstrated that, whereas 1 of 110 WT BASCs gave rise to a primary colony, the clonal frequency from Bmi1 Ϫ/Ϫ populations was 1 of 288 ( Fig. S5B ; P ϭ 0.0001).
When primary colonies were dissociated and replated for secondary colony formation, a profound self-renewal defect in BASCs lacking Bmi1 was revealed. Cells from Bmi1 Ϫ/Ϫ primary colonies did not form any secondary colonies, whereas Bmi1 ϩ/ϩ and Bmi1 ϩ/Ϫ formed secondary colonies equivalently (Figs. 4B  and S5C ). These data demonstrate that Bmi1 is required for proliferation and self-renewal of BASCs in culture, suggest that the BASC defects we observed in vivo were cell intrinsic.
Importantly, Bmi1-deficiency did not impair the differentiation potential of BASCs. Bmi1 Ϫ/Ϫ BASCs formed threedimensional structures similar to those seen in WT cultures when plated in differentiation conditions (Fig. S5D) . Both WT and mutant BASCs were multipotent, giving rise to bronchiolar and alveolar cells, and there was no statistically significant difference in differentiation frequency between the genotypes ( Fig. S5D ; data not shown). These results suggest that the primary defects in Bmi1-mutant BASCs are a result of self-renewal abrogation rather than altered differentiation.
We reasoned that the limitation on self-renewal capacity in BASCs from Bmi1-null animals could in part be explained by misregulation of the Ink4a/Arf locus. When we analyzed BASCs directly after sorting, we found that the levels of p19 ARF mRNA are increased 19-fold Ϯ 8 in the Bmi1-null population ( Fig. 4C ; P Ͻ 0.02), but the increase in p16 levels was not significant (P ϭ 0.1). However, once the BASCs were cultured, we observed an increase in the levels of both p16 and p19 ARF transcripts (Fig.  4D) . To determine what role misregulation of the Ink4a/Arf locus plays in the impairment of the Bmi1-deficient BASCs, we used a retroviral shRNA-GFP vector with a hairpin that targets both p16 and p19 ARF to knockdown expression of these two transcripts. Quantitative PCR showed that levels of p16 and p19 ARF mRNA were reduced Ϸ85% and Ϸ70%, respectively, in the Bmi1-null BASCs infected with the hairpin compared with the control vector ( Fig. 4D ; P ϭ 0.01 and P ϭ 0.02). As a result, p16 and p19
ARF mRNAs were present at comparable levels in Bmi1 Ϫ/Ϫ ;sh p16/p19ARF BASCs and Bmi1 ϩ/ϩ ;sh empty BASCs ( Fig.  4D ; P ϭ 0.9 and P ϭ 0.2). In the Bmi1 ϩ/ϩ ;sh p16/p19ARF BASCs, p16 and p19 ARF mRNAs were reduced to subphysiological levels relative to the Bmi1 ϩ/ϩ ;sh empty controls ( Fig. 4D ; P ϭ 0.02 and P ϭ 0.03). Primary colonies from Bmi1 Ϫ/Ϫ ;sh p16/p19ARF BASCs were significantly larger than Bmi1 Ϫ/Ϫ ;sh empty colonies ( Fig. 4E ; P ϭ 0.003), yet the Bmi1 Ϫ/Ϫ ;sh p16/p19ARF colonies did not reach the same size as the Bmi1 ϩ/ϩ ;sh empty colonies (P ϭ 0.002). This partial rescue also applied to the clonal frequency: 1 of 245 plated cells formed colonies in the Bmi1 Ϫ/Ϫ ;sh p16/p19ARF cultures compared with 1 of 367 in the Bmi1 Ϫ/Ϫ ;sh empty BASC cultures ( Fig. S5E; P ϭ 0.05 ). An examination of secondary colony formation showed that, whereas Bmi1 Ϫ/Ϫ ;sh empty BASCs did not form any secondary colonies, Bmi1 Ϫ/Ϫ ;sh p16/p19ARF BASCs were capable of producing secondary colonies in 25% of the wells plated with 1,000 primary colony cells (Figs. 4F and S5F; P Ͻ 0.02). Notably, the frequency of the Bmi1 Ϫ/Ϫ ;sh p16/p19ARF BASC secondary colonies was significantly lower than those arising from the Bmi1 ϩ/ϩ ;sh empty BASCs, even though these two genotypes have comparable p16 and p19 ARF mRNA levels. Taken together, these data show that increased levels of Ink4a/Arf inhibit the proliferation and self-renewal potential of Bmi1-deficient BASCs in vitro. The observed partial rescue suggests that either other downstream targets of Bmi1 are involved in establishing these properties, or that the BASCs have suffered irreversible consequences because of constitutive Bmi1 deficiency. Importantly, these data indicate that Bmi1 is critical for BASC proliferation and self-renewal, the key stem cell property of BASCs.
Discussion
Although the analysis of human tumors has shown a positive correlation between the overexpression of Bmi1 and the development of various epithelial tumors, a causal relationship had not been established before this study. We clearly establish that Bmi1 plays a key role in the development of lung cancer in the mouse. Thus, further investigation into the effects of Bmi1 expression on human lung cancer development or progression is warranted. Loss of Bmi1 has a profound and early effect on lung tumor development in a mouse model of lung cancer initiated by oncogenic K-ras G12D . There is a dramatic decrease in the number of lung lesions at very early time points in the Bmi1-deficient animals. Additionally, the lesions that arise appear to be blocked at an earlier stage of tumor development compared with WT animals and exhibit decreased proliferation. These data indicate that Bmi1 plays a vital role in very early epithelial tumor development. Studies have shown that Bmi1 is required for formation of hematopoietic and neural tumors, but normal development of these tissues was also impaired by Bmi1 deficiency (8, 12, 13) . Our data now reveal a role for Bmi1 in tumors originating from a tissue that normally develops under homeostatic conditions in adult Bmi1-deficient mice. Bmi1 is known to be up-regulated in a variety of epithelial tumors; therefore, we propose that Bmi1 may play a broad role in tumorigenesis in tissues that were previously considered to be independent of Bmi1 function, as judged by normal development in the absence of Bmi1.
Our data show that the requirement for Bmi1 in lung tumor development correlates with a requirement for Bmi1 to maintain the function of BASCs, the apparent tumor-initiating cells. BASCs are present at the appropriate levels in the Bmi1 Ϫ/Ϫ mice, and the lungs exhibit normal appearance. However, whereas expression of oncogenic K-ras or distal lung injury in vivo triggered the proliferation of BASCs in WT animals, this response was impaired by the loss of Bmi1. Similarly, Bmi1-deficient BASCs showed reduced proliferation and an inability to self-renew in culture. Clearly, Bmi1 is not the only determinant of BASCs' proliferative capacity. Recent studies already implicate negative regulators, such as MAPK and p27, in BASC control and lung tumorigenesis (26, 27) . Interestingly, we found that the defects in BASCs lacking Bmi1 were only uncovered when they encountered increased proliferative demand. This raises the possibility that other tissues with infrequent turnover may also rely on Bmi1 function in physiological settings that have not yet been examined.
These data lead to several interpretations about the functions of BASCs and Bmi1. First, the observed normal lung phenotype in Bmi1 Ϫ/Ϫ mice, despite defective BASC expansion in Bmi1 Ϫ/Ϫ adult lung, may suggest that BASCs are not required for lung development. Alternatively, BASCs may play a role in lung development, and the requirement for Bmi1 function may not occur in these cells until they have undergone a threshold of proliferative rounds (28) . Supporting the former, we and others have identified BASCs in adult lung but not during lung development (C. Kim, unpublished data) (29 (Figs. 2B and 4C ). This result is opposite to that seen in Bmi1-null neural tissue where p16, not p19 ARF , is more significantly up-regulated (10) . In ES cells, mutant K-ras causes up-regulation of p19 ARF , and Arf overexpression has been reported in latent K-ras G12D -induced lung tumors (30, 31) . Bmi1 overexpression contributes to Ras-induced transformation in culture and in vivo (6, 32) . The incomplete rescue of BASC function and lung tumorigenesis after p19 depletion, along with similar effects seen in both the hematopoietic and neural systems (14) (15) (16) , supports the notion that Bmi1 acts through both Arf-dependent and -independent mechanisms. We have some evidence to suggest that levels of p16 increase in the Bmi1-null total lung and BASCs on loss of Arf, suggesting a potential compensatory mechanism, which may, in part, explain the partial rescue (Dovey and Lees, unpublished data). However, the failure of Arf and p16 knockdown to fully rescue the proliferation of BASCs in vitro suggests that Bmi1 has targets beyond the Ink4a/Arf locus, although we cannot rule out any irreversible effects of the Bmi1 deficiency. Additional work is required to explore the relevant downstream targets of Bmi1 that may contribute to Bmi1's role in lung stem cell function and tumorigenesis.
The dependence of diverse tumor types on Bmi1 makes it an attractive target for cancer therapy. However, a dangerous side effect of depleting Bmi1 function in cancer patients would be abrogation of normal tissue stem cell function. Studies to determine whether there are mechanistic differences between the roles of Bmi1 in cancer cells versus stem cells will be crucial to identify more amenable strategies to eliminate cancer cells without affecting tissue homeostasis.
Materials and Methods
The materials and methods used for immunohistochemistry, IF, quantitative RT-PCR, naphthalene treatment, differentiation cultures, and RNA interference can be found in SI Text.
Mice and Tissues. Bmi1 knockout mice (8), K-ras LA2 mice (23) , and WT littermates were maintained on a mixed background (C57BL/6 ϫ 129/sv), and Bmi1 and K-ras LA2 mice were interbred. Arf (24) mice were maintained on a 129/sv background and interbred with K-ras LA2 ; Bmi1 mice. Four-and nine-week-old mice were killed for lung tumor analysis or IF BASC analysis. Tissue preparation was as described in ref. 23 .
BASC Sorting and Culture. Single cell suspensions and FACS analysis were performed as described in ref. 22 , with the following modifications: lungs were incubated with 2 g/ml collagenase/dispase (in HBSS-Mg-Ca) for 45 min at 37°C and then incubated with 0.002% DNase for 10 min on ice. BASC cultures and regression analysis were conducted as described in ref. 22 . Statistics. Statistical analysis of the limiting dilution assays was done by using L-calc software (Stem Cell Technologies). For the comparison of the distribution of BASC number per TB with the distribution of lung tumor stages, the Cochran-Armitage test was performed with MStat software. Other analyses were done by using the two-tailed Student's t test.
